Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Paraproteinemias 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia 1Kidney Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

cabozantinib 5Nivolumab 4Ipilimumab 4Axitinib 4pembrolizumab 3Blood Specimen Collection 3zimberelimab 2atezolizumab 2Surveys and Questionnaires 2Sunitinib 2Irinotecan 2temsirolimus 1spartalizumab 1salicylhydroxamic acid 1palbociclib 1orellanine 1olaparib 1liposomal doxorubicin 1lenvatinib 1gallium Ga 68 dotatate 1fludarabine 1brodalumab 1belzutifan 1aldesleukin 1adagrasib 1Vincristine 1Temozolomide 1Taxes 1Selenomethionine 1Ropivacaine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Neoplasms × Blood Cell Count × 90 days × Clear all
NCT07485114 2026-03-20

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Tel-Aviv Sourasky Medical Center

Recruiting
300 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡